Evaluation of [۹۹mTc]Tc-HYNIC-PSMA-۱۱ avidity in subtypes of renal cell carcinoma tumors
Publish place: Iranian Journal of Nuclear Medicine، Vol: 32، Issue: 1
Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 53
This Paper With 7 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IRJNM-32-1_005
تاریخ نمایه سازی: 8 بهمن 1402
Abstract:
Introduction: Renal cell carcinoma (RCC) is one of the most lethal urologic malignancies. The role of prostate-specific membrane antigen (PSMA) in prostate cancer is well known. PSMA has been shown in other tumors including renal cell carcinoma. [۹۹mTc]Tc-HYNIC-PSMA-۱۱ SPECT/CT is known as a cost effective alternative to [۶۸Ga]Ga-PSMA in prostate cancer. We prospectively evaluated the bio-distribution and diagnostic role of ۹۹mTc-HYNIC-PSMA SPECT/CT in patients with renal tumors before surgery; and also investigated whether the intensity of Tc-PSMA uptake will be different based on tumor histopathology.Methods: ۱۴ patients with primary renal tumors, clinically suspicious for RCC, underwent [۹۹mTc]Tc-HYNIC-PSMA-۱۱ SPECT/CT before surgery. All SPECT/CT images were reviewed separately. For quantitative analysis, volume of interest (VOI) was drawn over the tumor as well as the liver and maximum and mean counts were determined.Results: In visual analysis, all renal lesions showed decreased uptake compared to the adjacent parenchymal tissue and liver. Whole body [۹۹mTc]Tc-HYNIC-PSMA-۱۱ scan in all cases could detect the region of tumoral lesion and the size and limits of the tumor were compatible with CT findings and histopathologic results. The ratio of maximum count of the tumor to the mean count of the liver showed no statistically significant difference between different subtypes (P value =۰.۵۰); however, the mean value was higher in clear renal cell RCC compared to non-clear cell RCC type (۱.۴۰ vs ۱.۲۳).Conclusion: In our study, the low and inconsistent uptake of [۹۹mTc]Tc-HYNIC-PSMA-۱۱ in primary tumor of RCC suggest that this radiopharmaceutical is not an ideal agent for imaging this patient population.
Keywords:
Authors
Yasaman Fakhar
Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran
Atena Aghaee
Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran
Hamidreza Ghorbani
Department of Urology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Somaye Barashki
Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran
Kamran Aryana
Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad, Iran
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :